Compare BZ & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZ | IBRX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.5B |
| IPO Year | 2021 | 2015 |
| Metric | BZ | IBRX |
|---|---|---|
| Price | $13.95 | $8.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $23.00 | $12.57 |
| AVG Volume (30 Days) | 3.0M | ★ 11.0M |
| Earning Date | 05-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $15.92 | $88.59 |
| Revenue Next Year | $12.78 | $131.15 |
| P/E Ratio | $22.61 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $12.85 | $1.95 |
| 52 Week High | $25.26 | $12.43 |
| Indicator | BZ | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.72 | 54.39 |
| Support Level | $13.02 | $7.77 |
| Resistance Level | $14.81 | $8.51 |
| Average True Range (ATR) | 0.50 | 0.58 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 49.18 | 69.14 |
Kanzhun's Boss Zhipin job platform connects job seekers and employers. Boss Zhipin is China's largest online recruitment platform based on monthly active users, or MAU, and was established in 2014. Kanzhun earns revenue by providing services to enterprise customers primarily through its mobile app, which promotes engagement between recruiters and workers and operates on a recommendation basis powered by artificial intelligence. The platform specializes in transportation, logistics, construction, and service-based industries. About 85% of the companies looking to hire are small and medium-size enterprises. Its main competitors are 58.com, 51job, and Zhilian Zhaopin. Tencent has a 9.2% stake in Kanzhun.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.